Ana Carolina Bastos Sant'Anna Silva

This study identifies arginine synthesis pathway and ASS1 as key factors in mRNA translation reprogramming and ICI resistance in cutaneous melanoma, showing that targeting ASS1 can restore sensitivity to anti-PD-1.

This study shows that combining a HDAC3 inhibitor with 5-Azacitidine enhances anti-tumor effects against DLBCL in vitro and in vivo, with reduced toxicity compared to single agents.

This study identifies MELK as a key driver of metabolic adaptation and therapy resistance in melanoma, showing that inhibiting MELK can sensitize resistant cells to immunotherapy.